Human cell models: a breakthrough in clinical prediction and industrial productivity
As a pioneering biotech company, Univercell-Biosolutions has coupled the potential of human hiPS with cellular reprogramming and directed differentiation technologies. Together these innovations yield purified populations of specific human cell types (cardiomyocytes, endothelial cells, beta cells) for drug-discovery applications. Univercell-Biosolutions has developed Mesopure® to provide a pure (>99%) population of cardiovascular progenitors as well as a pure population of Nkx2.5+ cardiac populations and quiescent ventricular cardiomyocytes .
Univercell-Biosolutions works with clinicians, academics and industry leaders to develop next-generation homogeneous, mature, functional and differentiated human cells with physiological characteristics closely matching those of adult differentiated cells in vivo.
Univercell-Biosolutions’ goals are to accelerate the discovery of new therapeutics and to reduce the drug failure rate in clinical trials.